Cargando…
Therapeutic impact of determination of RAS mutations in the plasma of patient with colorectal cancer
Stage IV colorectal cancer treatment includes targeted therapy depending on RAS status. During disease progression, loss or gain of RAS mutations could happen, supporting the hypothesis of the evolutionary pressure of therapy. Circulating tumor DNA (ctDNA) are nucleic acids released to the bloodstre...
Autores principales: | Macedo, F, Monteiro, J, Pereira, T. Cunha, Monteiro, A.R., Felix Soares, R., Bonito, N, Sousa, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123636/ https://www.ncbi.nlm.nih.gov/pubmed/35611253 |
Ejemplares similares
-
Spectrum of K ras mutations in Pakistani
colorectal cancer patients
por: Murtaza, B.N., et al.
Publicado: (2013) -
Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019) -
The impact of RAS mutation on the treatment strategy of colorectal cancer
por: Pirvu, Edvina Elena, et al.
Publicado: (2023) -
RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer
por: Zhu, Liuying, et al.
Publicado: (2020) -
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)